Patents Represented by Attorney John P. Cooper & Dunham LLP White
  • Patent number: 6043783
    Abstract: A windowpane antenna apparatus for use in a vehicle according to the present invention, includes a plurality of conductive strips arranged in a windowpane of the vehicle so as to have a predetermined pattern, function designation switches turned on to transmit/receive predetermined waves, an arithmetic unit for performing an arithmetic operation of obtaining a combination of the plurality of conductive strips in order to form a desired antenna having antenna characteristics matching a function designated by the function designation switches, and a selective connecting switch for selecting one or some of the conductive strips based on the combination of the conductive strips obtained by the arithmetic unit and connecting the selected some of the conductive strips to form the desired antenna.
    Type: Grant
    Filed: January 30, 1998
    Date of Patent: March 28, 2000
    Assignee: Harada Industry Co., Ltd.
    Inventors: Hiroshi Endo, Masatoshi Saito, Hiroyuki Tachihara, David Briggs
  • Patent number: 6043796
    Abstract: A clutch for a motor driven antenna according to the present invention includes a driving member rotated by a driving motor, a driven member for transmitting a rotating force of the driving member to an antenna element, and a clutch element for frictionally transmitting the rotating force of the driving member to the driven member. The clutch element includes recesses formed on a rotating track of one of opposing sides of the driving member and driven member, projections formed on a rotating track of the other side so as to be fitted into the recesses when the driving member and the driven member are rotated relative to each other, and anti-slip members protruded near the recesses such that a sliding frictional force caused at the tip end contact portions of the projections exceeds a maximum load of the antenna element including the driven member when the antenna element is extended or retracted.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: March 28, 2000
    Assignee: Harada Industry Co., Ltd.
    Inventors: Masaki Shinkawa, Shinichi Saito
  • Patent number: 6040149
    Abstract: The subject invention provides a purified membrane-bound ceramide-activated protein kinase having an apparent molecular weight of about 110 kD as determined by SDS polyacrylamide gel electrophoresis, which protein kinase is capable of specifically phosphorylating the threonine residue in a Thr-Pro- or a Thr-Leu-Pro-containing polypeptide. The subject invention also provides a method of determining whether an agent is capable of specifically inhibiting the phosphorylation activity of the ceramide-activated protein kinase. The subject invention further provides a method of determining whether an agent is capable of specifically stimulating the phosphorylation activity of the ceramide-activated protein kinase. The subject invention further provides a method of treating a subject having an inflammatory disorder. The subject invention further provides a method of treating a human subject infected with HIV so as to reduce the proliferation of HIV in the human subject.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: March 21, 2000
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Richard N. Kolesnick, Jun Liu, Yuhua Zhang
  • Patent number: 6040451
    Abstract: This invention is directed to novel indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: March 21, 2000
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Yoon T. Jeon, Charles Gluchowski
  • Patent number: 6040159
    Abstract: This invention describes compounds active against TNF-.alpha. mRNA. It further describes mRNA molecules capable of conferring stability to RNA in vivo. Possible mRNA molecules to be stabilized include ribozymes, antisense molecules and mRNA encoding polypeptides useful for protein production. The ribozymes and antisense molecules described herein are useful in mammals and plants, particularly suited for viral diseases. Methods of production and methods of use are also described.
    Type: Grant
    Filed: April 4, 1995
    Date of Patent: March 21, 2000
    Assignee: Gene Shears Pty. Limited
    Inventor: Mouldy Sioud
  • Patent number: 6036655
    Abstract: An apparatus and method to objectively measure sensory discrimination thresholds at a test site in the upper aero digestive tract of a patient. A time and pressure controlled puff of air is delivered to the input of a Y-shaped tube; one output branch of the Y-shaped tube delivers the puff of air to the patient and the other output branch delivers the puff of air to a pressure transducer, for measurement and display of the pressure.
    Type: Grant
    Filed: December 7, 1995
    Date of Patent: March 14, 2000
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Jonathan E. Aviv, John H. Martin
  • Patent number: 6034075
    Abstract: The present invention is directed to a method of treating polycystic ovarian syndrome (PCO) with calcium alone, with vitamin D alone, or with the combination calcium and vitamin D. This invention further provides a method of treating infertility in a woman which comprises administering to the subject an amount of calcium or a derivative thereof effective to treat the infertility. The present invention is also directed to a method of treating irregular menses (oligo/amenorrhea), acne, or hirsutism, insulin resistance, or infertility which comprises administering a combination of calcium or a derivative thereof and vitamin D or a derivative thereof in an amount effective to treat irregular menses (oligo/amenorrhea), acne, or hirsutism, insulin resistance, or infertility.
    Type: Grant
    Filed: March 19, 1998
    Date of Patent: March 7, 2000
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Susan Thys-Jacobs
  • Patent number: 6034223
    Abstract: This invention provides an immunoconjugate which comprises 1) a non-peptidyl toxin and 2) a CD4-gamma2 chimeric heavy chain homodimer linked thereto. This invention also provides an immunoconjugate which comprises 1) a gamma radiation-emitting radionuclide of low to moderate cytotoxicity and 2) a CD4-gamma2 chimeric heavy chain homodimer linked thereto. This invention further provides an immunoconjugate which comprises 1) a non-peptidyl toxin and 2) a heterotetramer comprising two heavy chains and two light chains, both heavy chains being either a) IgG2 heavy chains or b) chimeric CD4-IgG2 heavy chains, and both light chains being either a) kappa light chains or b) chimeric CD4-kappa light chains.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 7, 2000
    Assignee: Progenics Pharmaceuticals, Inc.
    Inventors: Paul J. Maddon, Graham P. Allaway
  • Patent number: 6030611
    Abstract: Improved methods for production of recombinant human superoxide dismutase and analogs thereof have been developed. Such superoxide dismutase or analogs may be used to catalyze the reduction of superoxide radicals thereby preventing or treating injury resulting from the presence of such superoxide radicals.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: February 29, 2000
    Assignee: Bio-Technology General Corp.
    Inventors: Marian Gorecki, Amnon Gonenne
  • Patent number: 6030955
    Abstract: The present invention provides methods of stimulating or inhibiting intracellular phosphorylation of tyrosine by a heparin-binding receptor which comprises contacting a cell having on its surface the heparin-binding receptor with a phosphorothioate oligonucleotide moiety of suitable length and base composition, such phosphorothioate oligonucleotide moiety being present in an effective amount. The invention further provides a method of inhibiting the formation of blood vessels in a subject which comprises administering to the subject an amount of a phosphorothioate oligonucleotide moiety of suitable length and base composition. The invention also provides a method of inhibiting proliferation of cells having a malignant phenotype in a subject which comprises administering to the subject an amount of a phosphorothioate oligonucleotide moiety of suitable length and base composition.
    Type: Grant
    Filed: March 21, 1996
    Date of Patent: February 29, 2000
    Assignee: The Trustees of Columbia University in The City of New York and ImClone Systems, Inc.
    Inventors: Cy Stein, Patricia Rockwell
  • Patent number: 6028932
    Abstract: A copy prevention method and apparatus for a digital video system is disclosed including the steps of: (a) adding a header area of a header start code and key field to a reproduced bit stream; (b) decrypting and transmitting the bit stream to which the header area is added; (c) detecting a key field of the decrypted and transmitted bit stream and detecting copy prevention information; and (d) encrypting the bit stream according to information detected from step (c) and recording it on tape.
    Type: Grant
    Filed: April 1, 1998
    Date of Patent: February 22, 2000
    Assignee: LG Electronics Inc.
    Inventor: Tae Joon Park
  • Patent number: 6027913
    Abstract: This invention provides methods of amplifying a sequence of interest present within a nucleic acid molecule. In addition, this invention provides a method of determining the nucleotide sequence of a sequence of interest present within a nucleic acid molecule (e.g. GAWTS and RAWTS) which can be used to sequence tissue specific genes (e.g. tsRAWTS) and genes accross species (e.g. zooRAWTS).In addition, this invention provides a method of synthesizing a polypeptide encoded for by a nucleic acid molecule (RAWIT). Further, the subject invention provides a method of determining an internal nucleotide sequence present within a nucleic acid molecule, and a method of determining a terminal nucleotide sequence present within a nucleic acid molecule (e.g. PLATS).Also provided for is a method of determining the nucleotide sequence of sequences present within a nucleic acid molecule which are adjacent to areas of known sequence (e.
    Type: Grant
    Filed: December 27, 1994
    Date of Patent: February 22, 2000
    Inventor: Steven S. Sommer
  • Patent number: 6025480
    Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian p57.sup.KIP2. This invention also provides vectors comprising the isolated nucleic acid molecule encoding a mammalian p57.sup.KIP2. This invention further provides a host vector system for the production of a mammalian p57.sup.KIP2. This invention also provides probes for the isolated nucleic acid molecule encoding a mammalian p57.sup.KIP2. This invention provides antibodies directed against a mammalian p57.sup.KIP2. This invention also provides transgenic animals comprising isolated nucleic acid molecules encoding a mammalian p57.sup.KIP2. Finally, this invention provides different uses of the mammalian p57.sup.KIP2.
    Type: Grant
    Filed: April 3, 1995
    Date of Patent: February 15, 2000
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Joan Massague, Mong-Hong Lee
  • Patent number: 6020341
    Abstract: A quinone imine enediyne possessing cytotoxic activity towards cancer cells having general structure (I) wherein R.sub.1, R.sub.2 and R.sub.3 are independently the same or different and are H, Br, Cl, F, NH.sub.2, CO.sub.2 H, OH, linear or branched alkyl, etc.; wherein R.sub.4 is H, OH or linear or branched alkoxy, linear or branched alkoxycarbonyl, etc.; wherein R.sub.5 is H, Br, Cl, F, O.dbd., OH or S--SR, or linear or branched alkyl, etc.; wherein R.sub.6 is H, Br, Cl, F, CO.sub.2 H, OH or S--SR', or linear or branched alkyl, etc.; wherein R.sub.7 is H, OH or S--SR", or linear or branched alkyl, linear or branched alkoxycarbonyl, linear or branched alkoxy or linear or branched hydroxyalkyl; and wherein R, R' and R" are independently the same or different and are linear or branched alkyl, linear or branched acyl or linear or branched alkoxyalkyl.
    Type: Grant
    Filed: October 16, 1997
    Date of Patent: February 1, 2000
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Samuel J. Danishefsky, Matthew D. Shair, Taeyoung Yoon, Ting-Chao Chou, Karoline K. Mosny
  • Patent number: 6020619
    Abstract: The present invention intends to provide a radioactive rays detection semiconductor device comprises a substrate, an insulating layer formed on the substrate, p-type Si films formed on the insulating layer and equal in resistance value change rates due to temperature change and different in thickness so as to differ in the changes of the resistance values corresponding to the change of the total dose of the radioactive rays, an insulating film covering the p-type Si films, electrodes deposited in contact holes which are formed in the insulating film to reach both end of the p-type Si films, and Al wiring connecting the electrodes close to each other.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: February 1, 2000
    Assignees: Doryokuro Kakunenryo Kaihatsu Jigyodan, Mitsubishi Heavy Industries, Ltd.
    Inventors: Takao Wada, Yuzo Ishibashi, Shigeru Ishii, Yoshikatsu Kuroda
  • Patent number: 6017470
    Abstract: This invention provides a compound having the structure: ##STR1## wherein rings A and B represent independent electron accepting ring systems and wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are the same or different and are H, substituted or unsubstituted, saturated or unsaturated alkyl, alkenyl, cycloalkyl, aryl, or arylalkyl, --SR, --NRR', --OR, --OC(O)R, SC(O)R, --SCR, wherein R and R' are independently substituted or unsubstituted, saturated or unsaturated alkyl, alkenyl, cycloalkyl, aryl, or arylalkyl.This invention also provides thin films comprising a compound having the above structure or suitable derivatives thereof.This invention further provides liquid crystal display devices and non-linear optical devises comprising a compound having the above structure or a suitable derivative thereof.
    Type: Grant
    Filed: April 12, 1996
    Date of Patent: January 25, 2000
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Thomas J. Katz, Colin P. Nuckolls
  • Patent number: 6015819
    Abstract: A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.
    Type: Grant
    Filed: April 1, 1997
    Date of Patent: January 18, 2000
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Charles Gluchowski, Carlos C. Forray, George Chiu, Theresa A. Branchek, John M. Wetzel, Paul R. Hartig
  • Patent number: 6013500
    Abstract: This invention provides an isolated mammalian nucleic acid molecule encoding a PAK4 serine/threonine kinase. This invention provides an isolated nucleic acid molecule encoding a mutant homolog of the mammalian PAK4 serine/threonine kinase whose amino acid sequence is set forth in FIG. 1A (SEQ ID NO: 2). This invention provides a fusion protein comprising a PAK4 serine/threonine kinase or a fragment thereof and a second peptide. This invention provides a purified mammalian PAK4 serine/threonine kinase. This invention provides a protein comprising substantially the amino acid sequence set forth in FIG. 1A. This invention provides a monoclonal antibody directed to an epitope of a PAK4 serine/threonine kinase. This invention provides a method of inhibiting PAK4 function comprising administering a ligand comprising an amino acid domain which binds to a GTP binding protein so as to inhibit binding of the GTP binding protein to PAK4.
    Type: Grant
    Filed: May 21, 1998
    Date of Patent: January 11, 2000
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Audrey Minden
  • Patent number: 6013623
    Abstract: This invention provides a method for treating a condition associated with oxidative stress in a subject which comprises administering to the subject an amount of a heme-peptide effective to treat the condition associated with oxidative stress in the subject. The subject may be a mammal. The mammal may be a human being. The condition associated with oxidative stress may be an inflammatory condition, an allergic condition or an auto-immune condition.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: January 11, 2000
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Abraham Spector, Wanchao Ma, Ren-Rong Wang
  • Patent number: 6010875
    Abstract: Plasmids are provided which upon introduction into a suitable Eschericia coli host render the host capable of effecting expression of DNA encoding a desired naturally-occurring polypeptide or polypeptide analog thereof under the control of the deo P1-P2 promoter. Further plasmids are also provided which thermoinducibly direct expression of eucaryotic genes under the control of a .lambda. P.sub.L promoter and a thermolabile repressor protein present on the same plasmid under the control of a deo P1 promoter. These plasmids have been inserted into various hosts, some of which contain DNA encoding the repressor protein.Such plasmids may be used to produce polypeptides such as human copper/zinc superoxide dismutase, hMnSOD-hGPX fusion polypeptides, human manganese superoxide dismutase, human growth hormone, bovine growth, porcine growth, human growth hormone-apolipoprotein E fused polypeptides, apolipoprotein E and various fibronectin domains.
    Type: Grant
    Filed: July 25, 1996
    Date of Patent: January 4, 2000
    Assignee: Bio-Technology General Corp.
    Inventor: Meir Fischer